Abstract
The COVID-19 pandemic led to millions of deaths worldwide after its emergence in 2020. The SARS-CoV-2 virus primarily affects respiratory function, but immune dysregulation leading to systemic inflammation, endothelial dysfunction, and coagulopathy can predispose to systemic complications including hematologic and vascular complications. Treatment strategies for patients with COVID-19 have rapidly evolved and the effectiveness and safety of antithrombotic agents have been evaluated in multiple clinical trials. The findings have spurred interest in the prevention and treatment of the hematologic and vascular complications of non-COVID-19 respiratory infections. This review is focused on hematological and vascular complications of COVID-19, including their pathophysiology, clinical manifestations, and management. Because of the perpetually changing nature of the disease, the review places previous data in temporal contexts and outlines potential next steps for future research in COVID-19 and other severe respiratory infections.